The recovery in Core Laboratories’ (NYSE: CLB) financial results continued gaining momentum during the second quarter, with revenue and earnings both climbing by double digits. But the overall results were mixed, since revenue came in below the company’s guidance range while earnings hit the high end of its forecast. Further, the company sees the market entering a transitional period in the upcoming quarters, which will slow down its recovery.